Stroke
Conditions
Keywords
brain-derived neurotrophic factor, exercise, BDNF, lifestyle medicine
Brief summary
This is a pilot study to determine whether a lifestyle medicine intervention following stroke may increase levels of Brain-Derived Neurotrophic Factor (BDNF).
Detailed description
This is a substudy of the study entitled Assessing a Multi-Disciplinary Lifestyle Medicine Intervention Following Stroke, specifically looking at the effects of lifestyle change on brain-derived neurotrophic factor (BDNF). BDNF has emerged as a key facilitator of neuroplasticity to improve motor learning and rehabilitation after stroke. Aerobic exercise has been shown to increase levels of BDNF in multiple parts of the central nervous system and therefore may facilitate neuroplasticity and motor recovery. While BDNF levels appear to be increased for up to 1 hour following a bout of aerobic exercise, it is unclear whether regular aerobic exercise over weeks to months can increase baseline BDNF levels in humans following stroke. An single nucleotide polymorphism exists on the BDNF gene in 30-50% of the human population that results in an amino acid change from valine (val) to methionine (met) at position 66 (val66met) of the precursor peptide proBDNF. The presence of the met allele results in a 25% reduction in activity-dependent secretion of BDNF in the CNS. The Wellness in Rehabilitation program at the VA Palo Alto Health Care System is a lifestyle medicine intervention for patients following stroke. It is a 12-week program involving weekly meetings that include exercise (particularly aerobic exercise), nutrition, stress management, education, and group support. Participants are encouraged to perform healthy lifestyle behaviors (i.e. exercise) daily at home, and a health coach calls each patient weekly to support the behavior change process. Participants in the Wellness in Rehabilitation program who elect to participate in the research study will have blood drawn at baseline, week 6, and week 12. Blood draws will be performed in the morning prior to exercise, and week 6 will additionally include a blood draw within 30 minutes of completing a bout of aerobic exercise. Following completion of the study, plasma BDNF levels (measured as nanograms per milliliter) will then be measured at all 4 time points (baseline, week 6 pre-exercise, week 6 post-exercise, and week 12). In addition, BDNF genotype will be measured using the baseline sample. Participants will also complete bike or treadmill exercise testing at baseline and week 12 to determine pre- and post-program cardiovascular fitness levels (measured as VO2 max and estimated metabolic equivalents), and will also complete a 6-minute walk test. They will be asked to record their exercise daily and will additionally complete the Physical Activity Scale for Individuals with Physical Disabilities at baseline and week 12 time points.
Interventions
BEHAVIORALWellness in Rehabilitation program
The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
Sponsors
Stanford University
Spaulding Rehabilitation Hospital
VA Palo Alto Health Care System
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* History of prior stroke (ischemic or hemorrhagic) or transient ischemic attack * Ability to ambulate at least 10 feet with minimal to moderate assistance * Ability to travel to intervention site on a weekly basis.
Exclusion criteria
* Cerebral aneurysm * Concurrent pregnancy * Serious terminal illnesses (e.g. end stage renal disease, heart failure (class IV), cirrhosis (class C), metastatic cancer) * Any injury or illness preventing participation in regular aerobic exercise * Moderate-severe dementia or cognitive decline
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BDNF level - Final | Week 12 | Plasma BDNF protein levels, expressed in nanograms per milliliter, measured prior to any exercise upon completion of intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BDNF level - Post-exercise | Week 6 | Plasma BDNF protein levels, expressed in nanograms per milliliter, measured immediately following bout of aerobic exercise. |
| BDNF Genotype | Baseline | Genotyping of venous blood samples to determine ValVal, MetMet, and ValMet distribution. |
| Cardiovascular Fitness - VO2 max | Week 12 | Measured as VO2 max (ml/kg/min). |
| Cardiovascular Fitness - METs | Week 12 | Measured as estimated metabolic equivalents (kcal/kg/hour). |
| 6-minute Walk Test | Week 12 | Total distance walked 6 minutes on a flat surface. |
Countries
United States
Contacts
Primary ContactJeffrey Krauss, MD
Backup ContactWindy McNerney, PhD
Outcome results
None listed